Key Highlights

  • ResMed declared a quarterly Dividend of US$0.66 per NYSE share, equal to US$0.066 per ASX CDI.
  • The ex-dividend date is 11 November 2026, with record on 12 November and payment on 17 December.
  • The dividend is unfranked and paid in Australian dollars at the record-date exchange rate.
  • The amount is unchanged from the August declaration, which lifted the quarterly payout by 10 per cent.

ResMed Inc. (ASX:RMD) has one of the next confirmed entries among upcoming dividends on the ASX, after the sleep and respiratory care company declared a quarterly dividend of US$0.66 per share alongside its first quarter results for fiscal year 2027. For holders of the company's CHESS Depositary Interests (CDIs) on the ASX, that works out to US$0.066 per CDI, with an ex-dividend date of Wednesday 11 November 2026, a Record Date of Thursday 12 November and a payment date of Thursday 17 December 2026.

What ResMed Declared for the September Quarter

ResMed's board declared the US$0.66 quarterly dividend with its results for the three months to 30 September 2026. The company said the ex-dividend date of 11 November applies to both its New York Stock Exchange common stock and its ASX-listed CDIs, so investors on both markets need to hold their securities before that date to qualify.

The dividend is unchanged from the previous quarter. When ResMed reported its fourth quarter and full fiscal year 2026 results in August, it lifted the quarterly dividend by 10 per cent to US$0.66 per share. That payment went ex-dividend on 19 August 2026, carried a record date of 20 August and was paid on 24 September 2026.

ResMed also noted that, under a Waiver from the ASX, it would not process conversions between CDIs and NYSE shares from 11 November through to 12 November 2026 inclusive.

How the CDI Structure Changes the Numbers

ResMed is incorporated in the United States, and its ASX Quotation is in the form of CDIs. Ten CDIs are equivalent to one share of NYSE common stock, which is why the US$0.66 per share dividend becomes US$0.066 per CDI.

The company declares its dividend in US dollars, but CDI holders are paid an equivalent amount in Australian dollars. ResMed has said the conversion is based on the Exchange Rate on the record date, which for this payment is 12 November 2026. The final Australian dollar amount is therefore not known until the record date has passed.

Because ResMed is not an Australian taxpayer in the way an Australian-incorporated company is, its dividends carry no franking credits. The company's ASX dividend notices for 2026 have described the payments as unfranked. Investors comparing ResMed with domestic dividend payers will therefore need to Factor in both the absence of franking and the currency translation.

First Quarter Fiscal 2027 Results Behind the Dividend

The quarterly payout came with results showing Revenue of US$1,415 million for the September quarter, up 6 per cent on the same quarter a year earlier and up 7 per cent on a core constant currency basis. GAAP gross Margin was 61.5 per cent, while the non-GAAP gross margin was 62.5 per cent, an expansion of 50 basis points.

GAAP Operating Income was US$453 million, representing an Operating Margin of 32.0 per cent. GAAP Net Income was US$418 million and GAAP Diluted Earnings per Share rose 23 per cent to US$2.92. Non-GAAP diluted earnings per share increased 14 per cent to US$2.91.

Operating cash flow for the quarter was US$422 million and free cash flow was US$374 million. ResMed said it bought back US$936 million of its own stock in the quarter and paid US$95 million in dividends, returning more than US$1.0 billion to shareholders in total. Chairman and chief executive Mick Farrell said: "Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points," and the company linked part of its capacity for Capital returns to proceeds from the divestiture of its MatrixCare business.

Key Dates for ResMed Holders in the Weeks Ahead

For the current payment, the timeline is straightforward. Investors need to own ResMed CDIs before the market opens on Wednesday 11 November to be entitled to the dividend. Buying on or after the ex-date means the seller, not the buyer, receives the payment.

The record date of Thursday 12 November is when the share registry takes a snapshot of who is entitled to be paid, and it also sets the exchange rate used to convert the payment into Australian dollars. Payment follows on Thursday 17 December 2026, about five weeks later, which is a longer gap than many domestic companies use.

ResMed's quarterly rhythm means it is one of a small number of ASX-quoted companies paying dividends four times a year. Its earlier 2026 payments followed the same pattern: the March quarter dividend of US$0.060 per CDI went ex-dividend on 13 May 2026 and was paid on 18 June, and the June quarter dividend of US$0.066 per CDI was paid on 24 September.

Where ResMed Sits Among Upcoming ASX Dividends

ResMed's ex-date lands in a busy fortnight for upcoming dividends on the ASX. Several companies with September financial year ends or September half-years are scheduled to report in November, and many of them set dividend timetables that run into December.

The 11 November ex-date also sits after the Reserve Bank of Australia's decision on 3 November 2026 to raise the cash rate target by 25 basis points to 4.85 per cent. The RBA board said Inflation "remains elevated" and is expected to remain above 3 per cent for the coming year. ResMed's payout, however, is set in US dollars and driven by its own cash flow and capital management settings.

For ResMed holders, the key variables between now and 17 December are the exchange rate on 12 November, which fixes the amount in Australian dollars, and the company's next quarterly results, which will determine the following dividend.

Key Takeaways

ResMed Inc. has declared a quarterly dividend of US$0.66 per NYSE share, equal to US$0.066 per ASX CDI, with an ex-dividend date of 11 November 2026, a record date of 12 November and payment on 17 December. The dividend is unfranked and paid in Australian dollars at the record-date exchange rate. It is unchanged from the August declaration, which lifted the quarterly payout by 10 per cent, and it follows first quarter fiscal 2027 revenue of US$1,415 million and more than US$1.0 billion returned to shareholders through Buybacks and dividends.